Ontology highlight
ABSTRACT:
SUBMITTER: Ding X
PROVIDER: S-EPMC4979061 | biostudies-literature | 2016 Aug
REPOSITORIES: biostudies-literature
Ding Xia X Ray Chaudhuri Arnab A Callen Elsa E Pang Yan Y Biswas Kajal K Klarmann Kimberly D KD Martin Betty K BK Burkett Sandra S Cleveland Linda L Stauffer Stacey S Sullivan Teresa T Dewan Aashish A Marks Hanna H Tubbs Anthony T AT Wong Nancy N Buehler Eugen E Akagi Keiko K Martin Scott E SE Keller Jonathan R JR Nussenzweig André A Sharan Shyam K SK
Nature communications 20160808
Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib has been approved for treatment of advanced ovarian cancer associated with BRCA1 and BRCA2 mutations. BRCA1- and BRCA2-mutated cells, which are homologous recombination (HR) deficient, are hypersensitive to PARPi through the mechanism of synthetic lethality. Here we examine the effect of PARPi on HR-proficient cells. Olaparib pretreatment, PARP1 knockdown or Parp1 heterozygosity of Brca2(cko/ko) mouse embryonic stem cells (mESCs), ca ...[more]